Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial

• Main Authors: Andrieux-Meyer, Isabelle, Tan, Soek-Siam, Thanprasertsuk, Sombat, Salvadori, Nicolas, Menetrey, Caroline, Simon, Francois, Cressey, Tim R., Said, Hajjah Rosaida Hj Mohd, Abu Hassan, Muhammad Radzi, Omar, Haniza, Tee, Hoi-Poh, Chan, Wah Kheong, Kumar, Suresh, Thongsawat, Satawat, Thetket, Kanawee, Avihingsanon, Anchalee, Khemnark, Suparat, Yerly, Sabine, Ngo-Giang-Huong, Nicole, Siva, Sasikala, Swanson, Alistair, Goyal, Vishal, Bompart, Francois, Pecoul, Bernard, Murad, Shahnaz
• Format: Article
• Published: Elsevier Inc 2021
• Subjects: RC Internal medicine
• Online Access: http://eprints.um.edu.my/34587/
• Institution: Universiti Malaya

Background In low-income and middle-income countries, affordable direct-acting antivirals are urgently needed to treat hepatitis C virus (HCV) infection. The combination of ravidasvir, a pangenotypic non-structural protein 5A (NS5A) inhibitor, and sofosbuvir has shown efficacy and safety in patients...